Low quality of evidence for glucosamine-based nutraceuticals in equine joint disease: review of in vivo studies.
Authors: Pearson W, Lindinger M
Journal: Equine veterinary journal
Summary
# Editorial Summary: Glucosamine-Based Nutraceuticals in Equine Joint Disease Over the past 15+ years, glucosamine and chondroitin sulphate products have become widespread in equine practice for managing arthritis and joint disease, yet Pearson and Lindinger's 2009 systematic review of in vivo studies reveals a troubling gap between commercial enthusiasm and scientific rigour. The authors applied standardised quality criteria to all 15 published equine studies on glucosamine-based nutraceuticals—including well-known products such as Cosequin and Cortaflex—setting a minimum confidence threshold of 60%, but found that only 3 papers met this standard. Significant experimental limitations across the literature, from inadequate study design to insufficient detail on outcome measures, undermine the reliability of positive findings and substantially limit practitioners' ability to draw evidence-based conclusions about clinical efficacy. Given the considerable investment by manufacturers in these products, the absence of methodologically robust research is particularly striking and represents a missed opportunity to establish credible efficacy data. Until new, high-quality trials are conducted with appropriate controls, blinding, and clearly defined endpoints, equine professionals should interpret promotional claims cautiously and recognise that current evidence does not provide the confidence needed to routinely recommend these nutraceuticals as primary interventions for joint disease management.
Read the full abstract on PubMed
Practical Takeaways
- •Current published evidence does not reliably support efficacy claims for glucosamine-based nutraceuticals in horses due to poor study quality—practitioners should view manufacturer claims with caution
- •Until higher-quality research becomes available, glucosamine products should not be recommended based on strong evidence of efficacy for equine joint disease
- •Consider the lack of robust evidence when counseling horse owners on nutraceutical investments for arthritis management
Key Findings
- •Only 3 of 15 published in vivo studies on glucosamine-based nutraceuticals met a minimum quality threshold of 60%
- •Most studies on commercial products (Cosequin, Cortaflex, Synequin, etc.) demonstrate encouraging manufacturer investment in research but fail to meet adequate quality standards
- •General quality of studies in this area is low, prohibiting meaningful interpretation of reported results